《大行報告》富瑞上調歌禮製藥-B(01672.HK)目標價至5元 評級「買入」
富瑞發表研究報告指,歌禮製藥-B(01672.HK)研發藥物ASC41,在非酒精性脂肪性肝炎(NASH)患者III期臨床數據中顯示對病情有幫助,令該行對藥物更感樂觀,就臨床試驗進展而言,ASC41是中國首個治療NASH的甲狀腺激素受體β(THRβ)激動劑候選藥物。
該行上調集團目標價,由4.4元升至5元,評級「買入」,認為集團銷售額將持續增長,市場份額不斷擴大,亦擁有待批准及商業化的關鍵資產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.